4-(4-溴-2-氟苯基氨基)-1-甲基-6-氧代-1,6-二氢吡啶-3-羧酸 | 821791-44-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-(4-溴-2-氟苯基氨基)-1-甲基-6-氧代-1,6-二氢吡啶-3-羧酸
• 英文名称: 4-(4-bromo-2-fluorophenylamino)-1-methyl-6-oxo-1,6-dihydropyridine-3-carboxylic acid
• 英文别名: 4-(4-bromo-2-fluoroanilino)-1-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxylic acid；4-(4-bromo-2-fluoroanilino)-1-methyl-6-oxopyridine-3-carboxylic acid
• CAS: 821791-44-0
• 化学式: C₁₃H₁₀BrFN₂O₃
• 分子量: 341.136
• InChiKey: CKPLIOQXBXJAKJ-UHFFFAOYSA-N

物化性质

• 沸点：
  412.8±45.0 °C(Predicted)
• 密度：
  1.756±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  69.6
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(4-溴-2-氟苯基氨基)-1-甲基-6-氧代-1,6-二氢吡啶-3-羧酸 在 盐酸 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 生成 4-(4-bromo-2-fluoroanilino)-N-(2-hydroxyethoxy)-1-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxamide
  参考文献：
  名称：

  Potent and Selective Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors. 1. 4-(4-Bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones

  摘要：

  The role of MEK 1,2 in cancer tumorgenesis has been clearly demonstrated preclinically, and two selective inhibitors are currently undergoing clinical evaluation to determine their role in the human disease. We have discovered 4-(4-bromo-2-fluorophenylamino)-1-methylpyridin-2(1H)-ones as a new class of ATP noncompetitive MEK inhibitors. These inhibitors exhibit excellent cellular potency and good pharmacokinetic properties and have demonstrated the ability to inhibit ERK phosphorylation in HT-29 tumors from mouse xenograft studies.

  DOI：

  10.1021/jm050834y
• 作为产物：
  描述：

  4-羟基-1-甲基-6-氧代-1,6-二氢-吡啶-3-羧酸乙酯 在 lithium hydroxide 、 三乙胺 、 lithium diisopropyl amide 、 三氯氧磷 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 为溶剂， 反应 34.17h， 生成 4-(4-溴-2-氟苯基氨基)-1-甲基-6-氧代-1,6-二氢吡啶-3-羧酸
  参考文献：
  名称：

  Potent and Selective Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors. 1. 4-(4-Bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones

  摘要：

  The role of MEK 1,2 in cancer tumorgenesis has been clearly demonstrated preclinically, and two selective inhibitors are currently undergoing clinical evaluation to determine their role in the human disease. We have discovered 4-(4-bromo-2-fluorophenylamino)-1-methylpyridin-2(1H)-ones as a new class of ATP noncompetitive MEK inhibitors. These inhibitors exhibit excellent cellular potency and good pharmacokinetic properties and have demonstrated the ability to inhibit ERK phosphorylation in HT-29 tumors from mouse xenograft studies.

  DOI：

  10.1021/jm050834y

文献信息

• [EN] 5-SUBSTITUTED-4-`(SUBSTITUTED PHENYL)!AMINO!-2-PYRIDONE DEVIATIVES FOR USE AS MEK INHIBITORS<br/>[FR] DERIVES DE 4-[PHENYLAMINO (SUBSTITUE)]-2-PYRIDONE A SUBSTITUTION EN 5 EN TANT QU'INHIBITEURS DE LA MEK
  申请人：WARNER LAMBERT CO

  公开号：WO2005000818A1

  公开（公告）日：2005-01-06

  The present invention relates to 5-substituted-4-(substituted) phenylamino-2-pyridone derivatives of formula (I), pharmaceutical compositions and methods of use thereof as MEK inhibitors. Formula (I) wherein W is formula (II), formula (III), formula (IV), or formula (V); and R1-5 and Z are as defined in the claims.

  本发明涉及公式（I）的5-取代-4-(取代)苯胺基-2-吡啶酮衍生物，以及作为MEK抑制剂的药物组合物和使用方法。其中，公式（I）中W为公式（II）、公式（III）、公式（IV）或公式（V）；R1-5和Z如权利要求中所定义。
• Heterocyclic inhibitors of MEK and methods of use thereof
  申请人：Marlow L. Allison

  公开号：US20050256123A1

  公开（公告）日：2005-11-17

  Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R 1 , R 2 , R 7 , R 8 and R 9 , W, X and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.

  本文披露了式I的化合物及其药用盐和前药，其中R1、R2、R7、R8和R9、W、X和Y的定义如规范中所述。这些化合物是MEK抑制剂，在哺乳动物中用于治疗高增殖性疾病，如癌症和炎症，以及炎症病症。还披露了在哺乳动物中治疗高增殖性疾病的方法以及含有这些化合物的药物组合物。
• 5-Substituted-4-[(substituted phenyl) amino]-2-pyridone derivatives
  申请人：Black Leigh Shannon

  公开号：US20050026964A1

  公开（公告）日：2005-02-03

  The present invention relates to 5-substituted-4-(substituted)phenylamino-2-pyridone derivatives, pharmaceutical compositions and methods of use thereof.

  本发明涉及5-取代-4-(取代)苯基氨基-2-吡啶酮衍生物、制药组合物及其使用方法。
• HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF
  申请人：Marlow Allison L.

  公开号：US20090215834A1

  公开（公告）日：2009-08-27

  Disclosed are compounds of the Formula V and pharmaceutically acceptable salts and prodrugs thereof, wherein R 1 , R 2 , R 7 , R 8 and R 9 , and W are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, and inflammatory conditions in mammals. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases and inflammatory conditions in mammals and pharmaceutical compositions containing such compounds.

  本发明涉及公式V的化合物，以及其药学上可接受的盐和前药，其中R1、R2、R7、R8和R9以及W在说明书中定义。这些化合物是MEK抑制剂，可用于治疗哺乳动物的高增殖性疾病，如癌症和炎症，以及炎症状况。本发明还涉及使用这些化合物治疗哺乳动物的高增殖性疾病和炎症状况的方法，以及含有这些化合物的制药组合物。
• 5-substituted-4-[(substituted phenyl) amino]-2-pyridone derivatives
  申请人：Warner-Lambert Company, LLC

  公开号：US07273877B2

  公开（公告）日：2007-09-25

  The present invention relates to 5-substituted-4-(substituted)phenylamino-2-pyridone derivatives, pharmaceutical compositions and methods of use thereof.

  本发明涉及5-取代-4-(取代)苯基氨基-2-吡啶酮衍生物、制药组合物以及使用方法。